Homology Medicines (FIXX) Stock Price, News & Analysis

Company Overview

Homology Medicines, Inc., a genetic medicines company, focuses on transforming the lives of patients suffering from rare genetic diseases in the United States. The company offers proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors (AAVHSCs) to deliver genetic medicines in vivo either through a nuclease-free gene editing mobility, gene therapy or for various genetic disorders. Its earlier stage product candidates comprising HMI-202, an investigational gene therapy which completed IND-enabling studies for the treatment of metachromatic leukodystrophy; and HMI-104 which completed IND-enabling studies. Homology Medicines, Inc. was incorporated in 2015 and is headquartered in Bedford, Massachusetts.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.33 to $16.82
• 52-Week Range: N/A
• Volume: 22,300 shs
• Average Volume: 390,307 shs
• Market Capitalization: $978.01 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

FIXX Stock Analysis - Frequently Asked Questions

How were Homology Medicines' earnings last quarter?

Homology Medicines, Inc. (NASDAQ:FIXX) released its earnings results on Monday, November, 15th. The company reported ($0.27) EPS for the quarter, topping analysts' consensus estimates of ($0.30) by $0.03. The business had revenue of $1.68 million for the quarter, compared to the consensus estimate of $0.63 million. Homology Medicines had a negative net margin of 4,779.31% and a negative trailing twelve-month return on equity of 102.52%.

When did Homology Medicines' stock split?

Shares of Homology Medicines split on the morning of Wednesday, March 20th 2024. The 2-1 split was announced on Wednesday, March 20th 2024. The newly minted shares were payable to shareholders after the closing bell on Wednesday, March 20th 2024. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

When did Homology Medicines IPO?

Homology Medicines (FIXX) raised $100 million in an initial public offering (IPO) on Wednesday, March 28th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Evercore ISI served as the underwriters for the IPO and BTIG was co-manager.

What other stocks do shareholders of Homology Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Homology Medicines investors own include Editas Medicine (EDIT), NVIDIA (NVDA), Enovix (ENVX), Luminar Technologies (LAZR), Advanced Micro Devices (AMD), Ginkgo Bioworks (DNA) and Tesla (TSLA).

Company Calendar

• Last Earnings: 11/15/2021
• Today: 2/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:FIXX
• CUSIP: N/A
• CIK: 1661998
• Web: www.homologymedicines.com
• Phone: (781) 301-7277
• Fax: N/A
• Employees: 7
• Year Founded: 2015

Profitability

• EPS (Most Recent Fiscal Year): ($1.96)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-112,960,000.00
• Net Margins: -4,779.31%
• Pretax Margin: -7,532.87%
• Return on Equity: -102.52%
• Return on Assets: -74.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.25
• Quick Ratio: 7.25

Sales & Book Value

• Annual Sales: $1.16 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.26 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 58,130,000
• Free Float: 48,774,000
• Market Cap: $978.01 million
• Optionable: Optionable
• Beta: -0.10